


Ask a doctor about a prescription for Plerixafor Msn
Plerixafor
Plerixafor MSN Contains the Active Substance Plerixafor, Which Blocks a Protein on the Surface of Haematopoietic Stem Cells. This Protein "Binds" Haematopoietic Stem Cells in the Bone Marrow. Plerixafor Facilitates the Release (Mobilization) of Haematopoietic Stem Cells into the Bloodstream. Haematopoietic Stem Cells Are Collected Using a Device That Separates Different Blood Components (Apheresis Device), Then Frozen and Stored Until Transplantation.
Plerixafor MSN Is Used in Cases of Insufficient Mobilization, to Facilitate the Collection of Haematopoietic Stem Cells (for Their Collection, Storage, and Transplantation),
Before Starting Treatment with Plerixafor MSN, Discuss It with Your Doctor.
Tell Your Doctor If:
Your Doctor May Prescribe Regular Blood Teststo Monitor Your Blood Cell Count.
Plerixafor MSN Should Not Be Used to Mobilize Haematopoietic Stem Cells in Patients with Leukaemia (Blood or Bone Marrow Cancer).
Tell Your Doctor or Pharmacist About All Medicines You Are Taking or Have Recently Taken, as Well as Any Medicines You Plan to Take.
Pregnant Women Should Not Use Plerixafor MSN, as There Is Limited Experience with the Use of This Medicine in Pregnancy. If You Are Pregnant, Think You May Be Pregnant, or Plan to Have a Baby, Ask Your Doctor for Advice Before Using This Medicine. Women of Childbearing Age Should Use Contraception.
Do Not Breast-Feed While Using Plerixafor MSN, as It Is Not Known Whether This Medicine Passes into Human Milk.
Plerixafor MSN May Cause Dizziness and Fatigue, So If You Feel Dizzy, Tired, or Unwell, Do Not Drive.
This Medicine Contains Less Than 1 mmol (23 mg) of Sodium per Dose, Which Means It Is Essentially "Sodium-Free".
The Medicine Will Be Given to You by a Doctor or Nurse.
The Stem Cell Mobilization Procedure Starts with the Administration of Another Medicine Called G-CSF (Granulocyte Colony-Stimulating Factor). G-CSF Helps Plerixafor MSN Work. If You Need More Information About G-CSF, Ask Your Doctor and Read the Relevant Package Leaflet.
The Recommended Dose for Adults Is Either 20 mg (Fixed Dose) or 0.24 mg per Kilogram of Body Weight per Day.
The Recommended Dose for Children Aged 1 Year to Less Than 18 Years Is 0.24 mg per Kilogram of Body Weight per Day.
The Dose of Plerixafor MSN Is Determined Based on the Patient's Body Weight, So You Will Be Weighed in the Week Before the First Dose Is Given. If You Have Moderate or Severe Kidney Problems, Your Doctor Will Reduce the Dose.
Plerixafor MSN Is Given by Subcutaneous Injection (Under the Skin).
The First Dose of Plerixafor MSN Is Given 6-11 Hours Before the Start of Apheresis (Collection of Haematopoietic Stem Cells).
The Medicine Will Be Given for 2 to 4 Consecutive Days (Sometimes Up to 7 Days), Until a Sufficient Number of Stem Cells Have Been Collected for Transplantation. In Rare Cases, the Collection of Haematopoietic Stem Cells May Not Be Successful, and the Procedure May Need to Be Stopped.
Like All Medicines, This Medicine Can Cause Side Effects, Although Not Everybody Gets Them.
Very Common Side Effects(May Affect More Than 1 in 10 People)
Common Side Effects(May Affect Up to 1 in 10 People)
Uncommon Side Effects(May Affect Up to 1 in 100 People)
Rarely, Severe Gastrointestinal Side Effects (Diarrhoea, Vomiting, Abdominal Pain, and Nausea) May Occur.
In Clinical Trials, After Receiving Plerixafor MSN and G-CSF, There Were Uncommon Cases of Heart Attacks in Patients with Risk Factors for Heart Attack. Tell Your Doctor as Soon as Possible If You Get Chest Discomfort.
Tingling and Numbness Often Occur in Patients Receiving Anti-Cancer Treatment. These Symptoms Were Reported in About 1 in 5 Patients, but It Does Not Appear That They Occur More Frequently with Plerixafor MSN.
In Blood Tests, You May Also Have an Increased White Blood Cell Count (Leukocytosis).
If You Get Any Side Effects, Talk to Your Doctor or Pharmacist. This Includes Any Possible Side Effects Not Listed in This Leaflet.
You Can Also Report Side Effects Directly to the Regulatory Authority.
Keep This Medicine Out of the Sight and Reach of Children.
Do Not Use This Medicine After the Expiry Date Which Is Stated on the Carton and Label After EXP.
The Expiry Date Refers to the Last Day of That Month.
Store in a Refrigerator (2°C - 8°C).
Plerixafor MSN Should Be Used Immediately After Opening the Package.
Medicines Should Not Be Disposed of via Wastewater or Household Waste. Ask Your Pharmacist How to Dispose of Medicines No Longer Required. These Measures Will Help Protect the Environment.
Plerixafor MSN Is a Clear, Colourless to Pale Yellow Solution in a Glass Vial.
Each Pack Contains 1 Vial with 1.2 mL of Solution.
MSN Labs Europe Limited
KW20A, Corradino Park
Paola, PLA 3000
Malta
Tel: (+48) 699 711 147
Pharmadox Healthcare Limited
KW20A, Kordin Industrial Park
Paola, PLA 3000
Malta
MSN Labs Europe Limited
KW20A, Corradino Park
Paola, PLA 3000
Malta
Germany:
Plerixafor Vivanta Generics 20 mg/mL Injektionslösung, ENR: 7006277
Czech Republic:
Plerixafor MSN
Hungary:
Plerixafor MSN 20 mg/mL oldatos injekció
Poland:
Plerixafor MSN
Romania:
Plerixafor MSN 20 mg/mL soluţie injectabilă
Slovakia:
Plerixafor MSN
Bulgaria:
Плериксафор MSN 20 mg/mL инжекционен разтвор
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Plerixafor Msn – subject to medical assessment and local rules.